FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma
暂无分享,去创建一个
Elisabeth Kjellén | Anders Sandell | Johan Wennerberg | Tomas Ohlsson | S. Strand | T. Ohlsson | E. Brun | J. Wennerberg | Jan Tennvall | Eva Brun | E. Kjellén | J. Tennvall | A. Sandell | R. Perfekt | Roland Perfekt | Sven Erik Strand | Roland Perfekt
[1] K. Någren,et al. Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] Saroj P. Mathupala,et al. Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.
[3] A. Lammertsma,et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.
[4] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H Evans,et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas , 2000, British Journal of Cancer.
[6] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[7] M Schwaiger,et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] S. Reske,et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] H. Minn,et al. Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[11] K. Erlandsson,et al. An alternative method to normalize clinical FDG studies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] H. Müller-Gärtner,et al. Early changes in fluorine-18-FDG uptake during radiotherapy. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] T. Jones,et al. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.
[14] Saroj P. Mathupala,et al. Glucose Catabolism in Cancer Cells. , 1995, The Journal of Biological Chemistry.
[15] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Hoffman,et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy , 1994, Head & neck.
[17] Giampietro Gasparini,et al. Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .
[18] R L Wahl,et al. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] W. Vaalburg,et al. Radiation-induced inhibition of tumor growth as monitored by PET using L-[1-11C]tyrosine and fluorine-18-fluorodeoxyglucose. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] K. Erlandsson,et al. A new approach to three-dimensional image reconstruction in PET , 1991, Conference Record of the 1991 IEEE Nuclear Science Symposium and Medical Imaging Conference.
[22] L G Strauss,et al. The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] H. Minn,et al. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] H. Lodish,et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.
[25] C. Bohm,et al. Performance Study of the PC‐384 Positron Camera System for Emission Tomography of the Brain , 1984, Journal of computer assisted tomography.
[26] T Jones,et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas , 1983, Annals of neurology.
[27] M. Reivich,et al. THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.
[28] R. Wahl,et al. Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. , 2000, Acta oncologica.
[29] P. Marsden,et al. A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.
[30] K. Erlandsson,et al. Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. , 1997, Acta oncologica.
[31] J. Overgaard,et al. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] F Pozza,et al. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.
[33] K. Erlandsson,et al. A PET system based on 2-18FDG production with a low energy electrostatic proton accelerator and a dual headed PET scanner. , 1992, Acta oncologica.